skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Progesterone prevents development of neuropathic pain in a rat model: Timing and duration of treatment are critical

Original Research

(2161) Views  (668) Full article downloads

Authors: Henry JL, Dableh LJ

Published Date April 2011 Volume 2011:4 Pages 91 - 101
DOI: http://dx.doi.org/10.2147/JPR.S17009

Liliane J Dableh, James L Henry
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada

Background: Progesterone is emerging as an important protective agent against various injuries to the nervous system. Neuroprotective and remyelinating effects have been documented for this neurosteroid, which is synthesized by, and acts on, the central and peripheral nervous systems. Neuropathic pain is a severe, persistent condition that is generally resistant to treatment, and poses major personal, social, and economic burdens. The purpose of this study was to determine if single-dose or repeated progesterone administration would alleviate tactile hypersensitivity in a rat model of neuropathic pain, and to determine if early versus late initiation of treatment has an effect on the outcome.
Methods: Rats were unilaterally implanted with a polyethylene cuff around the sciatic nerve, and sensitivity to von Frey filament stimulation was measured over approximately 12 weeks.
Results: Rats given progesterone starting one hour after cuff implantation, and daily until day 4, exhibited tactile hypersensitivity similar to that of vehicle-treated rats for the duration of the study. When progesterone was started one hour after cuff implantation and given daily until day 10, rats exhibited no tactile hypersensitivity in the later part of the study, after treatment had stopped. When progesterone treatment was initiated at 20 days, once the model had been fully established, and given daily for 4 or even 11 days, no differences in withdrawal thresholds were observed compared with controls. Progesterone did not have any effect on withdrawal thresholds when given as a single dose, as measured at 30, 60 and 90 minutes after administration.
Conclusion: These results indicate that progesterone, when administered immediately after nerve injury, and for a sufficient period of time, can prevent the development of neuropathic pain, and may offer new strategies for the treatment of this highly debilitating condition.

Keywords: progesterone, neurosteroid, neuropathic pain, peripheral neuropathy, recovery, neuroprotection




 

Other articles by Dr James Henry



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Erratum
The selective neuronal nitric oxide synthase inhibitor 7-nitroindazole has acute analgesic but not cumulative effects in a rat model of peripheral neuropathy
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Current and future options for the management of phantom-limb pain